B. Incorrect! Magendie is a person who laid the foundations for animal physiology and pharmacology in the 18 th and 19 th centuries.

Size: px
Start display at page:

Download "B. Incorrect! Magendie is a person who laid the foundations for animal physiology and pharmacology in the 18 th and 19 th centuries."

Transcription

1 Pharmacology - Problem Drill 01: Introduction to Pharmacology Question No. 1 of is the science of drug preparation and medical use of drugs. Question #01 (A) Pharmacogenomics (B) Magendie (C) Materia medica (D) Pharmacology (E) Toxicology Pharmacogenomics is the study of how an individual s genetic makeup affects his or her response to a drug. Magendie is a person who laid the foundations for animal physiology and pharmacology in the 18 th and 19 th centuries. C. Correct! Materia medica is the science of drug preparation and medical use of drugs began to develop around the 17 th century. Pharmacological studies developed from this. Pharmacology is the study of the way that substances interact with the systems of the body to activate or inhibit its processes. Toxicology studies pharmacological processes that are undesirable. Materia medica is the science of drug preparation and medical use of drugs began to develop around the 17 th century. Pharmacological studies developed from this. The correct answer is (C).

2 Question No. 2 of 10 Instructions: (1) Read the problem and answer choices carefully (2) Work the problems on paper as needed (3) Pick the answer (4) Go back to review the core concept tutorial as needed. 2. Any substance that brings about a change in biological function through its chemical actions is called. Question #02 (A) Prodrug (B) Drug (C) Xenobiotic (D) Poison (E) Toxins B. Correct! Any substance that brings about a change in biological function through its chemical actions is called a drug. Feedback on Each Answer A xenobiotic is a drug molecule that is a chemical not synthesized by the body. A poison is a drug that causes harmful and undesirable effects. A toxin is a poison of biological origin. Any substance that brings about a change in biological function through its chemical actions Drug. The correct answer is (B).

3 Question No. 3 of A is a substance that is administered in its inactive form, but once Question #03 (A) Prodrug (B) Drug (C) Xenobiotic (D) Poison (E) Toxins A. Correct! Any substance that brings about a change in biological function through its chemical actions is called a drug. A xenobiotic is a drug molecule that is a chemical not synthesized by the body. A poison is a drug that causes harmful and undesirable effects. The correct answer is (A).

4 Question No. 4 of calculates the percentage of ionized & unionized molecules. Question #04 (A) Drug Shape (B) Henderson-Hasselbalch Equation (C) Ionization State of a Drug (D) Dose-response curve (E) Drug reactivity Drug shape does not determine ionization. B. Correct! The Henderson-Hasselbalch Equation calculates the percentage of ionized & unionized molecules. Think of the equation that describes the ionization state of the molecule. The dose-response curve is typically a sigmoid curve with a wide enough range to cover both low doses at which there is no observable response; the threshold level, at which a response is first evident; and the plateau at the top of the curve, which indicates the dose at which the maximum effect of the chemical is evident. Drug reactivity does not determine ionization. The Henderson-Hasselbalch Equation calculates the percentage of ionized & unionized molecules. This equation is used to calculate the percentage of ionized and unionized species. The equation states that the ph of the solution is equal to the pka of the drug plus the log of the fraction where the numerator is the concentration of the nonprotonated species and the denominator is the concentration of the protonated species. The correct answer is (B).

5 Question No. 5 of refers to the actions of the drug on the body. Question #05 (A) Pharmacokinetics (B) Pharmacodynamics (C) Pharmacogenomics (D) Pharmacology (E) Toxicology Pharmacokinetics is the actions of the body on the drug. B. Correct! Pharmacodynamics refers to the actions of the drug on the body. Pharmacogenomics is the study of how an individual s genetic make up affects his or her response to a drug. Pharmacology is the study of the way that substances interact with the systems of the body to activate or inhibit its processes. Toxicology studies pharmacological processes that are undesirable. Pharmacodynamics refers to the actions of the drug on the body. The duration of drug action depends upon how long the drug occupies the receptor. In some cases the drug is inactivated by metabolism resulting in termination of action. The correct answer is (B).

6 Question No. 6 of Two agents producing opposing physiological effects are called. Question #06 (A) Chemical antagonism (B) Pharmacokinetic antagonism (C) Physiological antagonism (D) Partial Agonist (E) Prodrug Chemical antagonism is the interaction of two substances in solution so that the effect of the active drug is lost. Pharmacokinetic antagonism is one drug affecting the absorption, metabolism or excretion of another drug. C. Correct! Two agents producing opposing physiological effects are called Physiological antagonism. Partial agonists produce a lower response at full receptor occupancy than full agonists and have intermediate efficacy. Two agents producing opposing physiological effects are called physiological antagonism. The correct answer is (C).

7 Question No. 7 of Drugs that cause harmful and undesirable effects are called: Question #07 (A) Prodrugs (B) Drugs (C) Xenobiotics (D) Poisons (E) Toxins Any substance that brings about a change in biological function through its chemical actions is called a drug. A xenobiotic is a drug molecule that is a chemical not synthesized by the body. D. Correct! A poison is a drug that causes harmful and undesirable effects. Drugs that cause harmful and undesirable effects are called poisons. The correct answer is (D).

8 Question No. 8 of produces a lower response at full receptor occupancy than full agonists and have intermediate efficacy. Question #08 (A) Chemical antagonism (B) Pharmacokinetic antagonism (C) Physiological antagonism (D) Partial Agonist (E) Prodrug Chemical antagonism is the interaction of two substances in solution so that the effect of the active drug is lost. Pharmacokinetic antagonism is one drug affecting the absorption, metabolism or excretion of another drug. Two agents producing opposing physiological effects are called Physiological antagonism. D. Correct! Partial agonists produce a lower response at full receptor occupancy than full agonists and have intermediate efficacy. Partial agonists produce a lower response at full receptor occupancy than full agonists and have intermediate efficacy. The correct answer is (D).

9 Question No. 9 of initiates changes in cell function, producing effects of various types. Question #09 (A) Antagonists (B) Reversible competitive antagonists (C) Agonists (D) Non-competitive antagonists (E) Xenobiotics Antagonists prevent agonists from activating receptors. Reversible competitive antagonism progressively inhibits the agonist response; at maximal concentrations, they completely prevent the response. C. Correct! Agonists initiate changes in cell function, producing effects of various types. Non-competitive antagonism blocks the chain of events that leads to the production of a response by the agonist. Xenobiotic is a drug molecule that is a chemical not synthesized by the body. Agonists initiate changes in cell function, producing effects of various types. Their potency depends upon their affinity (the tendency to bind to receptors) and efficacy (the ability to initiate changes once bound). The correct answer is (C).

10 Question No. 10 of is the interaction of two substances in solution so that the effect of the active drug is lost. Question #10 (A) Pharmacokinetic antagonism (B) Physiological antagonism (C) Pharmacodynamic effect (D) The Dose-Response Relationship (E) Chemical antagonism Pharmacokinetic antagonism occurs when one drug affecting the absorption, metabolism or excretion of another drug. Physiological antagonism occurs when two agents produce opposing physiological effects. Pharmacodynamic effect is the duration of drug action depends upon how long the drug occupies the receptor. Dose-response describes the relationship between exposure to a chemical and the magnitude of the response. E. Correct! Chemical antagonism is the interaction of two substances in solution so that the effect of the active drug is lost. Chemical antagonism is the interaction of two substances in solution so that the effect of the active drug is lost. An example is the inactivation of lead by chelating agents. The correct answer is (E).

INTRODUCTION TO PHARMACOLOGY

INTRODUCTION TO PHARMACOLOGY INTRODUCTION TO PHARMACOLOGY Pharmacology is the study of how chemicals interact with the body Endogenous hormones, growth factors, etc Exogenous drugs Two areas of study Pharmacodynamics Interaction of

More information

Key Aspects of Non-Clinical Pharmacology and Pharmacokinetics in the Evaluation of Safety

Key Aspects of Non-Clinical Pharmacology and Pharmacokinetics in the Evaluation of Safety Safeguarding public health Key Aspects of Non-Clinical Pharmacology and Pharmacokinetics in the Evaluation of Safety David R Jones (david.jones@mhra.gsi.gov.uk) Expert Pharmacotoxicologist, Medicines and

More information

S9 Nonclinical Evaluation for Anticancer Pharmaceuticals

S9 Nonclinical Evaluation for Anticancer Pharmaceuticals S9 Nonclinical Evaluation for Anticancer Pharmaceuticals This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create

More information

Chimica Farmaceutica. Pharmacokinetics and related topics

Chimica Farmaceutica. Pharmacokinetics and related topics Chimica Farmaceutica Pharmacokinetics and related topics INTRODUCTION In order to produce its intended effect, a drug must be present at an appropriate concentration in the fluid surrounding the effect

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS European Medicines Agency London, 24 January 2008 Doc. Ref. EMEA/CHMP/SWP/258498/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS

More information

Pharmacokinetic & Pharmacodynamic Data Analysis

Pharmacokinetic & Pharmacodynamic Data Analysis Pharmacokinetic & Pharmacodynamic Data Analysis CONCEPTS AND APPLICATIONS 4TH EDITION REVISED AND EXPANDED Table of Contents 1. 1.1 1.2 1.3 1.4 1.5 2. 2.1 2.2 2.2.1 2.2.2 2.2.3 2.2.4 2.2.5 2.2.6 2.2.7

More information

The scope and historical development of modern pharmacology. Basic pharmacological terms, definitions. Drug regulation. Types of pharmacotherapy and

The scope and historical development of modern pharmacology. Basic pharmacological terms, definitions. Drug regulation. Types of pharmacotherapy and The scope and historical development of modern pharmacology. Basic pharmacological terms, definitions. Drug regulation. Types of pharmacotherapy and drug effects. General information 15 lectures topics

More information

Drug Discovery and Development PHG 311. Prof. Dr. Amani S. Awaad

Drug Discovery and Development PHG 311. Prof. Dr. Amani S. Awaad Drug Discovery and Development PHG 311 Prof. Dr. Amani S. Awaad Professor of Pharmacognosy Pharmacognosy Department, College of Pharmacy Salman Bin Abdulaziz University, Al-Kharj. KSA. Email: amaniawaad@hotmail.com

More information

Organic Pharmaceutical Chemistry: Prodrugs

Organic Pharmaceutical Chemistry: Prodrugs Organic Pharmaceutical Chemistry IV 1st Semester, Year 5 (2016-2017) Lecture 1 Organic Pharmaceutical Chemistry: Prodrugs Dr Asim A. Balakit Pharmaceutical Chemistry Dept., College of Pharmacy, Babylon

More information

Introduction PART. 1 Why Technicians Need to Study Pharmacology and Therapeutics. 2 Pharmacokinetics

Introduction PART. 1 Why Technicians Need to Study Pharmacology and Therapeutics. 2 Pharmacokinetics PART Introduction 1 1 Why Technicians Need to Study Pharmacology and Therapeutics 2 Pharmacokinetics Understanding Pharmacology for Pharmacy Technicians 1 CHAPTER 1 Why Technicians Need to Study Pharmacology

More information

Introduction to Pharmacology. Prepared by: Shaikh Abusufyan, M. Pharm (Pharmacology)

Introduction to Pharmacology. Prepared by: Shaikh Abusufyan, M. Pharm (Pharmacology) Introduction to Pharmacology Prepared by: Shaikh Abusufyan, M. Pharm (Pharmacology) Pharmacology is the science of drugs (Greek: Pharmacon=Drug;logos=is course) In a broad sence it deals with interaction

More information

6 Enzymes II W. H. Freeman and Company

6 Enzymes II W. H. Freeman and Company 6 Enzymes II 2017 W. H. Freeman and Company The role of an enzyme in an enzyme-catalyzed reaction is to: A. bind a transition state intermediate, such that it cannot be converted back to substrate. B.

More information

CHAPTER 4. Milestones of the drug discovery

CHAPTER 4. Milestones of the drug discovery CHAPTER 4 Milestones of the drug discovery 4.Milestones of the drug discovery: Highlights the importance of the below critical milestones of the drug discovery and correlated to the current research. 1.

More information

Pharmacological Glossary

Pharmacological Glossary ND Pharma & Biotech Company Pharmacological Glossary Price Inquiry Definitions of commonly use pharmacological terms Absorbance: Absorbance is use for assays such as ELISA assays, protein an nucleic aci

More information

The course is taught by a team of UNC faculty and industry scientists. The course has been designed to provide the students an understanding of

The course is taught by a team of UNC faculty and industry scientists. The course has been designed to provide the students an understanding of Drug Metabolism MOPH 810 Fall 2009 Classes: 80 minute class twice a week Course Director: Dhiren R. Thakker Eshelman School of Pharmacy, UNC-Chapel Hill The course is taught by a team of UNC faculty and

More information

Comments and suggestions from reviewer

Comments and suggestions from reviewer Comments and suggestions from reviewer Page 1 of 13 Title: WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology: WHO/rDNA_DRAFT/12

More information

G/TBT/N/MYS/8 Proposal to enforce the Control of Drugs and Cosmetics Regulations 1984 on veterinary medicinal products.

G/TBT/N/MYS/8 Proposal to enforce the Control of Drugs and Cosmetics Regulations 1984 on veterinary medicinal products. G/TBT/N/MYS/8 Proposal to enforce the Control of Drugs and Cosmetics Regulations 1984 on veterinary medicinal products. The Health Minister of Malaysia, as conferred by subregulation 1(2) of the Control

More information

Challenges in receptor occupancy determination assays by flow cytometry in drug development

Challenges in receptor occupancy determination assays by flow cytometry in drug development Challenges in receptor occupancy determination assays by flow cytometry in drug development DATE 17 November 2016 PRESENTED BY Martine Broekema, Ph.D. Associated Director of Bioanalytical Sciences Large

More information

Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery

Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery Integration of FDSS7000 into a modular robotic system for Open Innovation drug discovery José Manuel Brea & María Isabel Loza BioFarma, Santiago de Compostela DRUG DISCOVERY OPEN INNOVATION CLOSED innovation

More information

Biomedical Sciences Graduate Program

Biomedical Sciences Graduate Program 1 of 6 Graduate School 250 University Hall 230 North Oval Mall Columbus, OH 43210-1366 January 11, 2013 Phone (614) 292-6031 Fax (614) 292-3656 Jeff Parvin, Joanna Groden Co-Graduate Studies Chairs Biomedical

More information

15/11/2017. Tramadol vs Tapentadol. Tramadol. Tramadol

15/11/2017. Tramadol vs Tapentadol. Tramadol. Tramadol Dr Andrew Dickman Consultant Pharmacist Royal Liverpool Hospital Tramadol vs Tapentadol Tramadol (+) ( ) Entered clinical practice in 1977 Launched in UK in 1997 Now one of the most widely prescribed drugs

More information

KING KHALID UNIVERSITY COLLEGE OF PHARMACY DEPARTMENT OF PHARMACEUTICS COURSE SPECIFICTION FOR PHARMACEUTICAL SCIENCES/PHARM-D

KING KHALID UNIVERSITY COLLEGE OF PHARMACY DEPARTMENT OF PHARMACEUTICS COURSE SPECIFICTION FOR PHARMACEUTICAL SCIENCES/PHARM-D KING KHALID UNIVERSITY COLLEGE OF PHARMACY DEPARTMENT OF PHARMACEUTICS COURSE SPECIFICTION FOR PHARMACEUTICAL SCIENCES/PHARM-D BY Mohammed Mahmoud Academic Session 147-8 1 st Semester (Semester No 71)

More information

Guideline on the non-clinical requirements for radiopharmaceuticals

Guideline on the non-clinical requirements for radiopharmaceuticals 1 2 3 15 November 2018 EMA/CHMP/SWP/686140/2018 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Draft Draft agreed by Safety Working Party October 2018 Adopted by CHMP for release for consultation

More information

Michaelis Menten Kinetics -Enzyme Kinetics, Binding and Cooperativity

Michaelis Menten Kinetics -Enzyme Kinetics, Binding and Cooperativity Michaelis Menten Kinetics -Enzyme Kinetics, Binding and Cooperativity Dr. M. Vijayalakshmi School of Chemical and Biotechnology SASTRA University Joint Initiative of IITs and IISc Funded by MHRD Page 1

More information

A. Incorrect! Enzymes are not altered or consumed by the reactions they catalyze.

A. Incorrect! Enzymes are not altered or consumed by the reactions they catalyze. CLEP Biology - Problem Drill 04: Enzymes and Cellular Metabolism No. 1 of 10 1. Which of the following statements about enzymes is correct? (A) Enzymes are consumed in a reaction. (B) Enzymes act by lowering

More information

SUBMISSION OF COMMENTS ON The Requirements for First-in-Human Clinical Trials for Potential High Risk Medicinal Products EMEA/CHMP/SWP/28367/2007

SUBMISSION OF COMMENTS ON The Requirements for First-in-Human Clinical Trials for Potential High Risk Medicinal Products EMEA/CHMP/SWP/28367/2007 European Medicines Agency SUBMISSION OF COMMENTS ON The Requirements for First-in-Human Clinical Trials for Potential High Risk Medicinal Products EMEA/CHMP/SWP/28367/2007 COMMENTS FROM The Biotechnology

More information

Unique PK-PD properties of biotechnology-based therapeutics [mabs] and First In Human dose considerations. [mabs -monoclonal antibodies ] Peter Lloyd

Unique PK-PD properties of biotechnology-based therapeutics [mabs] and First In Human dose considerations. [mabs -monoclonal antibodies ] Peter Lloyd Unique PK-PD properties of biotechnology-based therapeutics [mabs] and First In Human dose considerations [mabs -monoclonal antibodies ] Peter Lloyd Head of Pharmacokinetics-Pharmacodynamics Novartis Biologics

More information

Investigational New Drug Application

Investigational New Drug Application Investigational New Drug Application Regulatory Sponsor: Funding Sponsor: Study Product: Protocol Number: Name of the Sponsor-Investigator Department Name Address Phone Number Name of Primary Funding Institution

More information

From Candidate to Clinic: Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase

From Candidate to Clinic: Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase An Executive Summary From Candidate to Clinic: Strategies to Select, Assess, Formulate, and Deliver the Right Drug Candidate in the Early Phase Leveraging knowledge about an API s physicochemical properties

More information

Content Areas of the Pharmacy Curriculum Outcomes Assessment (PCOA )

Content Areas of the Pharmacy Curriculum Outcomes Assessment (PCOA ) Content Areas of the Pharmacy Curriculum Outcomes Assessment (PCOA ) Area 1.0 Basic Biomedical Sciences (10%) Area 2.0 Pharmaceutical Sciences (33%) Area 3.0 Social/Behavioral/Administrative Sciences (22%)

More information

Introduction to Drug Design and Discovery

Introduction to Drug Design and Discovery Introduction to Drug Design and Discovery Course: Drug Design Course code: 0510412 Dr. Balakumar Chandrasekaran Dr. Bilal Al-Jaidi Assistant Professors, Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy,

More information

Preclinical Development of Biologics: Case-by-case, so get off of my case!

Preclinical Development of Biologics: Case-by-case, so get off of my case! Preclinical Development of Biologics: Case-by-case, so get off of my case! Northeast Chapter SOT David Jacobson-Kram, Ph.D., DABT Office of New Drugs Center for Drug Evaluation and Research FDA October

More information

Lecture 7: 9/7. CHAPTER 7 Kinetics and Regulation

Lecture 7: 9/7. CHAPTER 7 Kinetics and Regulation Lecture 7: 9/7 CHAPTER 7 Kinetics and Regulation Chapter 7 Outline The rate or velocity of an enzymatic reaction Consider a simple reaction: The velocity or rate of the reaction is determined by measuring

More information

Pharmacogenomics information in SmPC

Pharmacogenomics information in SmPC Pharmacogenomics information in SmPC SmPC training presentation Note: for full information refer to the European Commission's Guideline on summary of product characteristics (SmPC) SmPC Advisory Group

More information

Dossier for marketing authorization in the European Union

Dossier for marketing authorization in the European Union Dossier for marketing in the European Union Maida Todi} Institute of Pharmacology, Clinical Pharmacology and Toxicology "Pavel Stern", Faculty of Medicine, University of Sarajevo, Abstract Extensive and

More information

PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis

PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis Disclaimer Contents are the opinion of the author and not that of Novartis

More information

The Exploratory IND (Phase 0) Concept

The Exploratory IND (Phase 0) Concept The Exploratory IND (Phase 0) Concept Joseph C. Hung Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA In recent years, the costs for drug research and development (R&D) have escalated despite

More information

DRUG DISCOVERY AND DEVELOPMENT-PRECLINICAL ASPECTS

DRUG DISCOVERY AND DEVELOPMENT-PRECLINICAL ASPECTS DRUG DISCOVERY AND DEVELOPMENT-PRECLINICAL ASPECTS 4th November 2014 Biomedicine Masters Program, Lund University Wayne Russell, PhD. ZEALAND PHARMA AGENDA TODAYS TALK: - INTRODUCTION TO DRUG DISCOVERY

More information

Saudi Pharmacist Licensure Examination (SPLE)

Saudi Pharmacist Licensure Examination (SPLE) Saudi Pharmacist Licensure Examination (SPLE) 1 SPLE Overview This document provides important information about the topics covered on the examination and the competency areas in which candidates will

More information

The views and opinions expressed in the following PowerPoint slides are

The views and opinions expressed in the following PowerPoint slides are Indications, Dosage and Administration, Clinical Studies, Clinical Pharmacology sections of a CCDS Presented by: Mary Jane Boyle Head, Worldwide Product Labeling Merck & Co., 13-October-2011 The views

More information

NANYANG TECHNOLOGICAL UNIVERSITY SEMESTER I EXAMINATION CBC922 Medicinal Chemistry. NOVEMBER TIME ALLOWED: 120 min

NANYANG TECHNOLOGICAL UNIVERSITY SEMESTER I EXAMINATION CBC922 Medicinal Chemistry. NOVEMBER TIME ALLOWED: 120 min AYAG TECLGICAL UIVERSITY SEMESTER I EXAMIATI 2006-2007 CBC922 Medicinal Chemistry VEMBER 2006 - TIME ALLWED 120 min ISTRUCTIS T CADIDATES 1. This examination paper contains TW (2) parts and comprises SIX

More information

ENZYMES. Unit 3 - Energy

ENZYMES. Unit 3 - Energy ENZYMES Unit 3 - Energy What is an enzyme? What do they do? What is an enzyme? What do they do? Key Things to remember: They are proteins They are catalysts They are reusable - not consumed in reaction

More information

COMMISSION DIRECTIVE 2009/120/EC

COMMISSION DIRECTIVE 2009/120/EC 15.9.2009 Official Journal of the European Union L 242/3 DIRECTIVES COMMISSION DIRECTIVE 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on

More information

Structure and content of an IMPD. What is required for first into man trial?

Structure and content of an IMPD. What is required for first into man trial? What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation

More information

Nonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies. Whitney S. Helms, PhD IOM, February 29,2016

Nonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies. Whitney S. Helms, PhD IOM, February 29,2016 Nonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies Whitney S. Helms, PhD IOM, February 29,2016 Disclaimer The views disseminated in this talk are my own and do not necessarily represent

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR

More information

参考資料. Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products. Draft

参考資料. Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products. Draft 参考資料 1 2 3 4 5 Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products Draft 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Table of contents 1.

More information

PHAR 7633 Chapter 23 Pharmacodynamic Models and Physiologically Based Pharmacokinetic Models

PHAR 7633 Chapter 23 Pharmacodynamic Models and Physiologically Based Pharmacokinetic Models PHAR 7633 Chapter 23 Pharmacodynamic Models and Physiologically Based Pharmacokinetic Models Student Objectives for this Chapter To understand the different types of concentration - effect relationships

More information

Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products

Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products Table of contents 1.Introduction...2 2.Scope...3 3.Discussion...4 3.1. Chemistry, manufacturing, and controls...4

More information

Guideline for Bioequivalence Studies of Generic Products. December 22, 1997

Guideline for Bioequivalence Studies of Generic Products. December 22, 1997 Guideline for Bioequivalence Studies of Generic Products December 22, 1997 Index Section 1: Introduction Section 2: Terminology Section 3: Tests A. Oral conventional dosage forms and enteric coated products

More information

DOWNLOAD OR READ : SAFETY EVALUATION TOXICOLOGY METHODS CONCEPTS AND RISK ASSESSMENT ADVANCES IN MODERN ENVIRONMENTAL TOXICOLOGY PDF EBOOK EPUB MOBI

DOWNLOAD OR READ : SAFETY EVALUATION TOXICOLOGY METHODS CONCEPTS AND RISK ASSESSMENT ADVANCES IN MODERN ENVIRONMENTAL TOXICOLOGY PDF EBOOK EPUB MOBI DOWNLOAD OR READ : SAFETY EVALUATION TOXICOLOGY METHODS CONCEPTS AND RISK ASSESSMENT ADVANCES IN MODERN ENVIRONMENTAL TOXICOLOGY PDF EBOOK EPUB MOBI Page 1 Page 2 safety evaluation toxicology methods pdf

More information

ORGANIZATION AND ROLE OF A PHASE I ONCOLOGY UNIT. Dr Philippe CASSIER Centre Léon Bérard, Lyon

ORGANIZATION AND ROLE OF A PHASE I ONCOLOGY UNIT. Dr Philippe CASSIER Centre Léon Bérard, Lyon ORGANIZATION AND ROLE OF A PHASE I ONCOLOGY UNIT Dr Philippe CASSIER Centre Léon Bérard, Lyon Outline Cancer & Oncology Drug development in oncology Specificity of phase I trials in oncology Study design

More information

PHARMACOLOGY. Dr Paul Spiers, Dept of Pharmacology & Therapeutics Tel ,

PHARMACOLOGY. Dr Paul Spiers, Dept of Pharmacology & Therapeutics Tel , PHARMACOLOGY COURSE COORDINATOR: Dr Paul Spiers, Dept of Pharmacology & Therapeutics Tel 896 2146, spiersj@tcd.ie ECTS Value 10 Credits Contact Hours 46 hrs lectures 2 tutorials 3 hr 2 computer sessions

More information

Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations Guidance for Industry

Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations Guidance for Industry Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation

More information

REGULATION OF GENE EXPRESSION

REGULATION OF GENE EXPRESSION REGULATION OF GENE EXPRESSION Each cell of a living organism contains thousands of genes. But all genes do not function at a time. Genes function according to requirements of the cell. Genes control the

More information

Basic Principles for Conducting Phase I Trials in the Japanese Population Prior to Global Clinical Trials

Basic Principles for Conducting Phase I Trials in the Japanese Population Prior to Global Clinical Trials Administrative Notice October 27, 2014 To: Prefectural Health Department (Bureau) Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare Basic

More information

Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products

Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products 1 2 3 17 January 2013 EMA/CHMP/13099/2013 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Joint MHLW/EMA reflection paper on the development of block copolymer micelle Agreed by Nanomedicines

More information

1. COURSE TITLE INTERACTION DRUG ORGANISM Course number Content area Course type Course level Year. 1.6.

1. COURSE TITLE INTERACTION DRUG ORGANISM Course number Content area Course type Course level Year. 1.6. 1. COURSE TITLE INTERACTION DRUG ORGANISM 1.1. Course number 32506 1.2. Content area Basic pharmacological concepts 1.3. Course type Complusory subject 1.4. Course level Master Degree 1.5. Year First 1.6.

More information

Cytochrome P450 Genotype Panel

Cytochrome P450 Genotype Panel DOB: Age: Gender: Visit Number (FIN): Patient Results Client: Physician: ARUP Test Code: 2013098 Collection Date: 11/29/2016 Received in lab: 11/30/2016 Completion Date: 12/07/2016 Gene Genotype Phenotype

More information

Graduate Courses: Advanced Pharmaceutics Prerequisites: Course No: Instructor: Credits: Description:

Graduate Courses: Advanced Pharmaceutics Prerequisites: Course No: Instructor: Credits: Description: The following is a listing of courses offered by the Graduate Program in Pharmaceutical Science. Prerequisites and brief descriptions are included for each course. For more information on a particular

More information

BASIC PHARMACOKINETICS AND PHARMACODYNAMICS

BASIC PHARMACOKINETICS AND PHARMACODYNAMICS BASIC PHARMACOKINETICS AND PHARMACODYNAMICS An Integrated Textbook and Computer Simulations SARA ROSENBAUM ~ WILEY A lohn WILEY & SONS, INC., PUBLICATION CONTENTS Preface 1 Introduction to Pharmacokinetics

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/32775/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ANNEX TO GUIDELINE ON SIMILAR BIOLOGICAL

More information

Models for Computer-Aided Trial & Program Design

Models for Computer-Aided Trial & Program Design Models for Computer-Aided Trial & Program Design Terrence Blaschke, M.D. VP, Methodology and Science Pharsight Corporation & Professor of Medicine & Molecular Pharmacology Stanford University MODELS What

More information

Application of PGx in PK at FDA: Experience and Expectations

Application of PGx in PK at FDA: Experience and Expectations Application of PGx in PK at FDA: Experience and Expectations EMEA-EFPIA Workshop Integrating PGx into Early Drug Development London UK 19 December 2008 Lawrence J. Lesko, Ph.D., F.C.P. Office of Clinical

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) POSITION PAPER ON NON-CLINICAL SAFETY STUDIES TO SUPPORT CLINICAL TRIALS WITH A SINGLE MICRODOSE

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) POSITION PAPER ON NON-CLINICAL SAFETY STUDIES TO SUPPORT CLINICAL TRIALS WITH A SINGLE MICRODOSE European Medicines Agency Evaluation of Medicines for Human Use London, 23 June 2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) POSITION PAPER ON NON-CLINICAL SAFETY STUDIES TO SUPPORT CLINICAL

More information

Documentation requirements for an initial consultation

Documentation requirements for an initial consultation Language : French or English Documentation requirements for an initial consultation Because of the wide range of medical devices which incorporate, as an integral part, an ancillary medicinal substance,

More information

Introduction to clinical trials Magnus Kjaer

Introduction to clinical trials Magnus Kjaer Introduction to clinical trials 2016-01-20 Magnus Kjaer One Definition of Clinical Trial NIH 2014 A research study in which one or more human subjects are prospectively assigned to one or more interventions

More information

Development of biopharmacy

Development of biopharmacy 31/10/2017 1 Development of biopharmacy Expression biopharmaceutics was composed By Gerhard Levy and it was written down by John G. Wagner in a publication from 1961 for the first time. Gerhard Levy Knowledge

More information

Consultation by a notified body on an ancillary medicinal substance integrated in a medical device

Consultation by a notified body on an ancillary medicinal substance integrated in a medical device Consultation by a notified body on an ancillary medicinal substance integrated in a medical device Documentation requirements for an initial consultation Language : French or English Because of the wide

More information

Pharmacology Lecture 5. Anticoagulants

Pharmacology Lecture 5. Anticoagulants Pharmacology Lecture 5 Anticoagulants General overview Anti-thrombotic Drugs Antiplatlets Anticoagulants Fibrinolytics Anticoagulants Indirect Thrombin Inhibitors Anti-thrombotic effect is exerted by interaction

More information

OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE

OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE OFFICE FOR RESEARCH PROCEDURE PROTOCOL & INVESTIGATIONAL BROCHURE, CONTENT, DESIGN, AMENDMENTS & COMPLIANCE 1. Purpose: To describe the procedures related to the development of protocol and investigational

More information

Pharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University.

Pharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. Pharmacology Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. 1 PHARMACODYNAMIC STUDIES A. Primary pharmacodynamics primary action in target

More information

IMMUNOLOGY Receptors of T cells are TCR T Cell Receptors which are present on the cell surface of T lymphocytes.

IMMUNOLOGY Receptors of T cells are TCR T Cell Receptors which are present on the cell surface of T lymphocytes. IMMUNOLOGY - 4 - What is an ANTIGEN? It is a molecule that can be recognized by a receptor and combine with it specifically and the receptor here is the one either produced by B cells or T cells: Receptors

More information

Global Development Challenges: Classical and Advanced Therapy Medicinal products

Global Development Challenges: Classical and Advanced Therapy Medicinal products Global Development Challenges: Classical and Advanced Therapy Medicinal products Beatriz Silva Lima imed, Lisbon University and Infarmed,, Portugal CHMP, CAT, SAWP Member and SWP Chair NONCLINICAL STUDIES

More information

History of ICH: The Common Technical Document structure and contents

History of ICH: The Common Technical Document structure and contents History of ICH: The Common Technical Document structure and contents DCVMN Common Technical Document (CTD) Workshop Brazil, 18 to 20 June 2018 Dr. Nora Dellepiane The realisation of the importance of an

More information

Bioreaction Kinetics Seungwook Kim Chem. & Bio. Eng.

Bioreaction Kinetics Seungwook Kim Chem. & Bio. Eng. Bioreaction Kinetics 2 2004 Seungwook Kim Chem. & Bio. Eng. Reference Chemistry and the Living Organism, 6 th edition, Molly M. Bloomfield, Lawrence J. Stephens, John Wiley & Sons, Inc. Enzymes 1. Most

More information

From Molecules To Medicine

From Molecules To Medicine From Molecules To Medicine A journey through research and development From Molecules To Medicine Bayer invests considerable resources in the research and development of new drugs, with the aim of improving

More information

Main Content Domain % of Operational Items # of Operational Items

Main Content Domain % of Operational Items # of Operational Items The PCOA content areas and subtopics for the 2016-2017 administration are based upon the outcomes from the US College of Pharmacy Curricula Survey. The assessment is composed of four content areas that

More information

The general concept of pharmacodynamics

The general concept of pharmacodynamics Asian PK/PD Educational Workshop The general concept of pharmacodynamics modeling the antibacterial effects relations PK / PD This part uses material from presentations of H. Derendorf (Gainesville, Fla.)

More information

Current Guidelines for Drug-drug Interaction Evaluation

Current Guidelines for Drug-drug Interaction Evaluation Current Guidelines for Drug-drug Interaction Evaluation Odette A Fahmi, PhD DDI-Edge Consulting, LLC June 2018 21 ST International Conference on Drug-Drug Interactions OUTLINE Recommended DDI approaches

More information

Juvenile toxicity studies with biopharmaceuticals : considerations and current practices

Juvenile toxicity studies with biopharmaceuticals : considerations and current practices Juvenile toxicity studies with biopharmaceuticals : considerations and current practices Shaun Maguire Toxicologist, Biologics Safety Assessment, MedImmune, Cambridge, UK maguires@medimmune.com AGAH Workshop

More information

Sequoia Education Systems, Inc. 1

Sequoia Education Systems, Inc.   1 Functional Diagnostic Medicine Training Program Mod 6 * FDMT 551A The Physiology and Biochemistry of (The Phases of Detoxification) Wayne L. Sodano, D.C., D.A.B.C.I. & Ron Grisanti, D.C., D.A.B.C.O., M.S.

More information

Guideline for the quality, safety and efficacy of follow-on biological medicinal products

Guideline for the quality, safety and efficacy of follow-on biological medicinal products Guideline for the quality, safety and efficacy of follow-on biological medicinal products 1. Introduction A follow-on biological medicinal product (hereinafter referred to as FOBMP) is considered as a

More information

Multi-Regional Studies and Bridging Studies. Simon Day, PhD Johns Hopkins University

Multi-Regional Studies and Bridging Studies. Simon Day, PhD Johns Hopkins University This work is licensed under a Creative Commons Attribution-nCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Introduction to clinical trials

Introduction to clinical trials Introduction to clinical trials Definition of a clinical trial A research activity that involves administration of a test treatment to some experimental unit in order to evaluate the treatment. Key words

More information

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research

Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities

More information

Chapter 21. Toxicity Testing

Chapter 21. Toxicity Testing Chapter 21 Toxicity Testing Toxicity Testing There are two purposes of toxicity testing. There is a quantitative effort to elucidate a dose effect relationship There is a qualitative determination of the

More information

The ABC s of Pharmacogenomics and Pharmacogenetics. Guillaume Pare MD, M.Sc., FRCPc Research Fellow Harvard Medical School

The ABC s of Pharmacogenomics and Pharmacogenetics. Guillaume Pare MD, M.Sc., FRCPc Research Fellow Harvard Medical School The ABC s of Pharmacogenomics and Pharmacogenetics Guillaume Pare MD, M.Sc., FRCPc Research Fellow Harvard Medical School Objectives Understand terms relating to pharmacogenomics and pharmacogenetics Understand

More information

FDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010

FDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010 FDA Public Hearing: Approval Pathway for Biosimilar and Interchangeable Biological Products November 2-3, 2010 1 The Biotechnology Industry Organization Over 1,100 members, including biotechnology companies,

More information

Guidance for Establishing Safety in First-in-Human Studies during Drug Development CONTENTS SUMMARY INTRODUCTION SCOPE

Guidance for Establishing Safety in First-in-Human Studies during Drug Development CONTENTS SUMMARY INTRODUCTION SCOPE Guidance for Establishing Safety in First-in-Human Studies during Drug Development CONTENTS SUMMARY...1 1. INTRODUCTION...1 2. SCOPE...2 3. MAIN GUIDANCE TEXT...2 3.1 Risk Factors...2 3.1.1 Mechanism of

More information

Guideline on similar biological medicinal products containing recombinant granulocyte-colony stimulating

Guideline on similar biological medicinal products containing recombinant granulocyte-colony stimulating 1 2 3 26 July 2018 EMEA/CHMP/BMWP/31329/2005 Rev 1 Committee for Medicinal Product for Human Use (CHMP) 4 5 6 7 Guideline on similar biological medicinal products containing recombinant granulocyte-colony

More information

Lipoidal permeability central to drug ADME Major barriers to drug discovery: dogma surrounding plasma protein binding and tissue concentration

Lipoidal permeability central to drug ADME Major barriers to drug discovery: dogma surrounding plasma protein binding and tissue concentration Lipoidal permeability central to drug ADME Major barriers to drug discovery: dogma surrounding plasma protein binding and tissue concentration Lipoidal permeability of typical antagonists / inhibitors

More information

Exploratory clinical trials workshop

Exploratory clinical trials workshop Exploratory clinical trials workshop Yves Donazzolo, Grenoble / Lyon Dominique Tremblay, Paris AGAH / Club Phase I meeting Lyon, April 28 & 29, 2009 Topics Introduction Definitions Nonclinical safety studies

More information

Biopharmaceutics. Lecture :1. Module Introduction and Introduction to Biopharmaceutics

Biopharmaceutics. Lecture :1. Module Introduction and Introduction to Biopharmaceutics Biopharmaceutics Lecture :1 Module Introduction and Introduction to Biopharmaceutics Assist. Lecturer Ali Yaseen Ali BSc Pharmacy MSc Industrial Pharmaceutical Sciences Dept. of Pharmaceutics School of

More information

Impact factor: 3.958/ICV: 4.10 ISSN:

Impact factor: 3.958/ICV: 4.10 ISSN: Impact factor: 3.958/ICV: 4.10 ISSN: 0976-7908 24 Pharma Science Monitor 8(2), Apr-Jun 2017 PHARMA SCIENCE MONITOR AN INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES Journal home page: http://www.pharmasm.com

More information

Acceptance of Foreign Clinical Data A U.S. Perspective

Acceptance of Foreign Clinical Data A U.S. Perspective Acceptance of Foreign Clinical Data A U.S. Perspective Robert L. Justice, M.D., M.S. 9 th Kitasato University Harvard School of Public Health Symposium Disclaimer The views expressed in this presentation

More information

The Role of Comparative Analyses for Evaluation of Generic Drug-Device Combinations in an ANDA

The Role of Comparative Analyses for Evaluation of Generic Drug-Device Combinations in an ANDA The Role of Comparative Analyses for Evaluation of Generic Drug-Device Combinations in an ANDA K. Witzmann, MD Inhalation and Drug-Device Combination Products Team Office of Research and Standards, Office

More information

PHYSICO-CHEMICAL, BIOLOGICAL OR MICROBIOLOGICAL TESTS OF MEDICINAL PRODUCTS

PHYSICO-CHEMICAL, BIOLOGICAL OR MICROBIOLOGICAL TESTS OF MEDICINAL PRODUCTS RADIOPHARMACEUTICALS Guideline Title Radiopharmaceuticals Legislative basis Directives 65/65/EEC, 75/318/EEC as amended, Directive 89/343/EEC Date of first adoption December 1990 Date of entry into June

More information

Regulatory Perspective

Regulatory Perspective Regulatory Perspective Presented by Dr Maria Isaac MASc, MD, PhD, Pharmaceutical Medicine Physician, Psychiatrist Senior Scientific Officer An agency of the European Union Disclaimer The views expressed

More information

How Targets Are Chosen. Chris Wayman 12 th April 2012

How Targets Are Chosen. Chris Wayman 12 th April 2012 How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench

More information